cross-referenced news and research resources about

 gadolinium logo
images:  google   yahoo YouTube

updated Sun. October 10, 2021

The Gadolinium Market report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the market. In this report, the Gadolinium market valuein 2017 and expected value to by the end of 2022 and growth rate between 2017 and 2022 is ...
Older patients, those with hypertension, and those with more bright spots on their brain scans (associated with brain aging) were more likely to show gadolinium in the vitreous chamber at 24 hours. In a minority of patients, both eye chambers showed gadolinium at two hours. In those patients, stroke tended to affect a larger ...

Because the positron moves so quickly through the water, it emits the optical equivalent of a sonic boom, called Cherenkov radiation. (Watchman is a shortening of Water Cherenkov Monitor of Antineutrinos.) Mixed in the water will be the element gadolinium, which will absorb the neutron generated in the ...
Gadolinium-based Contrast Media Market size is anticipated to see significant growth prospects from 2018 to 2022. The objective of Gadolinium-based Contrast Media market report is to provide a detailed analysis of Gadolinium-based Contrast Media industry and its impact based on applications and on ...
Gadolinium(III) Oxide Market report 2023 focuses on the major Types and Applications for the key players. Gadolinium(III) Oxide market research report also provides analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Gadolinium(III) Oxide market ...
The use of gadolinium-based contrast agents (GBCAs) in MRI brain studies was long thought to be safe for patients without severe renal insufficiency, but in 2014, researchers started finding evidence that GBCAs can leave traces of gadolinium (GD) behind in the brain. Interest in the subject has increased, ...

“Although the link between [gadolinium-based contrast agents] GBCA deposition and dentate T1 shortening is now well established, the clinical significance of intracranial GD accumulation, if any, remains unknown,” wrote corresponding author Vikas Agarwal, MD, with the department of radiology at the ...
A worldwide study, published in Current Problems in Diagnostic Radiology, revealed wide inconsistencies in reporting brain gadolinium deposition (GD) based on a lack of understanding and an effort to minimize anxiety in patients. “Although the link between [gadolinium-based contrast agents] GBCA ...
Gadolinium Market Report cover detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. The Gadolinium market report provides an in-depth overview of Product Specification, technology, product type and production analysis ...
What if gadolinium-based contrast agents (GBCAs) could be used at just 10% of current dose levels without significantly degrading image quality or contrast enhancement? Artificial intelligence (AI) could make that possible, according to research published in the Journal of Magnetic Resonance Imaging (J.
Cardiac magnetic resonance (CMR) stress T1 mapping outperformed gadolinium-based first-pass perfusion imaging in a head-to-head comparison, detecting obstructive CAD with a 0.97 area under the curve (AUC) versus a 0.91 AUC. Obstructive CAD was defined by fractional flow reserve (FFR) less than ...
The Ministry of Food and Drug Safety said it would revise the warning labels for eight types of gadolinium-based contrast agents (GBCAs), encompassing a total of 25 such products. The label changes will go into effect on Mar. 15. “Our ministry examined the safety information of GBCAs by comprehensively ...
Gadobutrol is a Gadolinium-based contrast agent used in diagnostic MRIs in adults and children to highlight areas in the central nervous system that have disrupted blood-brain barriers (BBB) or abnormal vascularity. It also works to expose the presence of breast disease, and detect stroke and tumor ...
Most patients suspected of having a stroke are given an MRI, typically with a contrasting agent such as gadolinium. Gadolinium is a harmless, transparent chemical; it remains in the blood stream and is filtered out by the kidneys in healthy people. But a stroke disrupts the blood-brain barrier, enabling the ...
Other studies since then have confirmed small amounts of gadolinium are retained in certain brain tissues in amounts roughly proportional to gadolinium exposure. One research team published a survey of people with self-reported symptoms and called it “gadolinium deposit disease.” In November, Gena ...
The Gadolinium-based Contrast Media Market Report covers the insightful data for business strategists, Growth Prospects and historical & futuristic cost and revenue over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the ...
The initial test subjected a sample of gadolinium to sequential magnetic fields, causing the sample to alternate between heating up and cooling down. Using precisely timed pumps to circulate water during those heating and cooling cycles, the system demonstrated sustained cooling power of about 10 ...

Gadolinium-based contrast agent (GBCA) also referred to as magnetic resonance imaging (MRI) contrast media or dyes are chemical substances that are used in magnetic resonance imaging based diagnostics. When administered into the body, gadolinium-based contrast agent enhances the quality of ...
Stroke-related brain damage can be assessed by studying the patient's eyes. In a new study published in Neurology, researchers from the National Institute of Health (NIH) found that the eyes of stroke patients had unusual bright specks. They believe that these were caused by a chemical called gadolinium ...
Compromises to the blood-brain barrier during stroke enable gadolinium to leak in and create bright spots on the brain that indicate points of damage. Researchers found that the same approach could be applied to the eyes, as the blood-ocular barrier can also experience damage during these episodes.
Gadolinium could be doing a lot more for cerebrovascular patients than previously thought. According to a group of researchers at the National Institutes for Health, the chemical agent could highlight not just abnormalities in routine brain MRIs, but identify the severity of incident stroke. Gadolinium has long ...
But a stroke can damage the tiny blood vessels and cause leakage in the blood-brain barrier, which allows some gadolinium to leak into the brain tissue. This shows up as bright spots on MRI scans. Between the eyes and the bloodstream, there is a similar barrier called the blood-ocular barrier. There is ...
Gadolinium, a contrast agent used to improve MRI imaging, has been shining a light on brain diseases and damage for years, but now scientists from the National Institutes of Health (NIH) believe it could reveal even more. With the chance discovery of the transparent chemical leaking into and then lighting ...
An unexpected finding involving gadolinium-based contrast agents and stroke patients has prompted researchers from the U.S. National Institutes of Health (NIH) to further explore the ocular effects of MRI exams in stroke patients. The research, published online Feb. 7 in Neurology, found that gadolinium ...
Trace amounts of gadolinium may remain for months or years in the body organs including bone (highest concentration), brain, liver, spleen, kidneys and skin. Consequences of gadolinium retention in the brain have not been established. Pathologic and clinical consequences of retention in skin and other ...
It's possible you haven't heard that my wife, Gena, and I are suing 11 Big Pharma companies. We don't need the money. It's a crime we're trying to stop. It's for Gena and all people who have suffered, are currently suffering and will suffer through gadolinium poisoning administered during routine MRIs.
This CAS 52093-29-5 – Gadolinium(III) trifluoromethanesulfonate Chemical World Consumption Report provides data on the net consumption of Gadolinium(III) trifluoromethanesulfonate in each of the countries listed. The substance covered (Gadolinium(III) trifluoromethanesulfonate) are classified by the ...
Gadolinium Market report provides Emerging Market trends, Manufacturer Share, Market Segmentation, regional outlook and comprehensive analysis on different market segments. The Gadolinium Market provides detailed analysis of Market Overview, Segmentation by Types, Potential Applications and ...
The Norrises claim the chemical poisoned Gena and she developed Gadolinium Deposition Disease following an otherwise routine MRI procedure. The couple claims Gena has been hospitalized numerous times after she suffered multiple debilitating bouts of pain and burning throughout her body ...
In previous years, MRI with and without intravenous gadolinium were performed to evaluate for the presence of an acoustic neuroma. However, with the development of the ultra high-resolution, non-enhanced fast spin echo (also known as CISS, FIESTA, or 3D MPR), a non-contrast (gadolinium) MRI has been shown to be ...
The anti-amyloid antibody BAN2401 from Biogen and Eisai flunked a phase II trial, failing to meet a primary endpoint at one year -- but the companies are pushing through to 18 months to look at biomarkers. The antibody is structurally different from Biogen's other amyloid-targeting drug, aducanumab.
The US Food and Drug Administration (FDA) announced last Tuesday that it will require that gadolinium-based contrast agents (GBCAs) used in MRI scans carry a class warning about their potential to stay in patients' brains and bodies for months or years. Previous reports have found, for example, that ...
Although the benefits outweigh the potential harms of all gadolinium-based contrast agents used for MRI scans, the FDA said these agents can remain in the body for months—even years—after a procedure. The FDA, which issued a class warning, said there were steps that can minimize the problem of ...
FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients' bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not ...
Healthcare professionals will now be required to provide medical information to all patients receiving gadolinium. In addition, they are advised to consider how much gadolinium will remain in a patient's body when choosing a gadolinium-based contrast agent (GBCA) for an MRI. Patients at higher risk for ...
The FDA has issued a drug safety communication about gadolinium-based contrast agents used in MRIs. It is requiring a new class warning and other safety measures for these products. Gadolinium-based contrast agents are usually cleared from the body through the kidneys, but trace amounts appear to ...
The FDA announced Dec. 19 that it's requiring a new class warning and additional safety measures for all gadolinium-based contrast agents (GBCAs) concerning gadolinium remaining in patients "for months to years after receiving these drugs." The FDA notes that gadolinium retention has not been ...
FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients' bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not ...
WASHINGTON -- All gadolinium contrast agents used in magnetic resonance imaging (MRI) must now carry a warning about their retention in the body, which has been linked to adverse renal effects, the FDA said Tuesday. "The FDA reviewed available data about the retention of gadolinium from ...
The FDA issued a new Drug Safety Communication Tuesday that requires a warning to be placed on all gadolinium-based contrast agents (GBCAs) for MRI use. The warning should alert providers about the possibility that gadolinium could be retained in the patient's body, including their brain, for an ...
This seems to be the impression that the ongoing regulatory debates in the U.S. about concerns surrounding gadolinium retention, is leaving patients with for now. The U.S. FDA has deemed the current clinical evidence as inconclusive of an adverse effect of gadolinium retention in the brain and body, ...
Action film star Chuck Norris and his wife Gena O'Kelley have filed a $10 million (£7.6 million) lawsuit against 11 pharmaceutical manufacturers and distributors. The pair holds these companies responsible for effects they are attributing to gadolinium contrast dye used during Gena's MRI scans. Chelated ...
On Thursday, a law firm announced it was representing Chuck Norris in a suit against three different companies for $10 million in damages. Norris and his wife, Gena, claim that she has gadolinium deposition disease from medical scans taken five years ago. But what is gadolinium? And how controversial ...
Gadolinium is a rare earth metal, silvery white, ductile and malleable. Gadolinium is employed in various application segments including electronics, medical equipment, imaging agents and nuclear reactors among others. Being a rare earth metal, the price of gadolinium have increased many folds over the ...
Mastering the art of balancing risks and benefits, according to Matthew Davenport, MD, from the University of Michigan, is what medicine is all about. When anecdotes about gadolinium-based contrast media agents allegedly poisoning patients became increasingly mainstream, its use in imaging ...
The Food and Drug Administration (FDA) issued a safety alert about gadolinium, the dye that's injected when our doctors order a brain MRI “with and without” contrast. The dye provides the contrast that “lights up” areas of MS inflammation in the brain. But the FDA advisory is sort of half-baked, leaving me to ...
The U.S. Food and Drug Administration (FDA) has updated a safety bulletin about gadolinium-based contrast agents (GBCAs), after studies raised new concerns about them. Doctors often use GBCAs to diagnose multiple sclerosis (MS), monitor disease activity and verify the effectiveness of MS therapies.
Global Gadolinium(III) Oxide Market Research Report 2017 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is ...
The U.S. Food and Drug Administration issued a safety announcement about some gadolinium-based contrast agents injected intravenously during an MRI scan to improve the visibility of organs and tissues. Gadolinium is a heavy metal, and there is evidence that trace amounts can be retained in the body.
Healthcare professionals will now be required to provide medical information to all patients receiving gadolinium. In addition, they are advised to consider how much gadolinium will remain in a patient's body when choosing a gadolinium-based contrast agent (GBCA) for an MRI. Patients at higher risk for ...


news and opinion




chemical elements: